-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On March 30, Sichuan Huiyu Pharmaceutical's 4 types of generic marketing application for levetiracetam injection concentrated solution has completed the approval process, waiting for the official announcement of the results
.
Levetiracetam is a TOP2 anti-epileptic drug, with terminal sales of more than 1 billion yuan in Chinese public medical institutions from 2018 to 2020
.
Figure 1: Source of product registration progress: NMPA official website The levetiracetam preparations currently on the market include levetiracetam injection concentrated solution, levetiracetam oral solution, levetiracetam tablets, levetiracetam Piracetam sustained-release tablets, of which the first three products have been included in the national procurement
.
Figure 2: Sales of levetiracetam in recent years (unit: 100 million yuan) Source: MINET And township health centers (referred to as Chinese public medical institutions) terminal anti-epileptic drug market, the sales of levetiracetam in 2018-2020 exceeded 1 billion yuan, and the growth rate in the first half of 2021 reached 5.
87%
.
Figure 3: Approved products of Sichuan Huiyu Pharmaceutical from 2022 to the present Source: new version database of Minet.
In January 2022, Sichuan Huiyu Pharmaceutical's bortezomib for injection was approved according to the new classification as a review.
If the concentrated solution of Piracetam for injection is successfully approved, it will become the company's second high-end injection approved for marketing this year
.
Figure 4: The latest product information of Sichuan Huiyu Pharmaceutical Source: CDE official website In recent years, Sichuan Huiyu Pharmaceutical has been deeply involved in the high-end injection market.
Up to now, there are 10 injections approved for marketing according to the new classification
.
On March 30, the company submitted an application for the listing of Category 3 generics for sodium thiosulfate injection, which is the first product to be reported for production this year
.
Sodium thiosulfate injection is listed on the national shortage drug list.
At present, only 3 companies have obtained approval, and no companies have reviewed it yet
.
Source: NMPA official website, CDE official website, Minet database.
The review data statistics are as of March 30.
If there are any mistakes or omissions, please correct me
.
Levetiracetam is a TOP2 anti-epileptic drug, with terminal sales of more than 1 billion yuan in Chinese public medical institutions from 2018 to 2020
.
Figure 1: Source of product registration progress: NMPA official website The levetiracetam preparations currently on the market include levetiracetam injection concentrated solution, levetiracetam oral solution, levetiracetam tablets, levetiracetam Piracetam sustained-release tablets, of which the first three products have been included in the national procurement
.
Figure 2: Sales of levetiracetam in recent years (unit: 100 million yuan) Source: MINET And township health centers (referred to as Chinese public medical institutions) terminal anti-epileptic drug market, the sales of levetiracetam in 2018-2020 exceeded 1 billion yuan, and the growth rate in the first half of 2021 reached 5.
87%
.
Figure 3: Approved products of Sichuan Huiyu Pharmaceutical from 2022 to the present Source: new version database of Minet.
In January 2022, Sichuan Huiyu Pharmaceutical's bortezomib for injection was approved according to the new classification as a review.
If the concentrated solution of Piracetam for injection is successfully approved, it will become the company's second high-end injection approved for marketing this year
.
Figure 4: The latest product information of Sichuan Huiyu Pharmaceutical Source: CDE official website In recent years, Sichuan Huiyu Pharmaceutical has been deeply involved in the high-end injection market.
Up to now, there are 10 injections approved for marketing according to the new classification
.
On March 30, the company submitted an application for the listing of Category 3 generics for sodium thiosulfate injection, which is the first product to be reported for production this year
.
Sodium thiosulfate injection is listed on the national shortage drug list.
At present, only 3 companies have obtained approval, and no companies have reviewed it yet
.
Source: NMPA official website, CDE official website, Minet database.
The review data statistics are as of March 30.
If there are any mistakes or omissions, please correct me
